Nuclear signalling by tumour-associated antigen EpCAM

EpCAM was found to be overexpressed on epithelial progenitors, carcinomas and cancer-initiating cells. The role of EpCAM in proliferation, and its association with cancer is poorly explained by proposed cell adhesion functions. Here we show that regulated intramembrane proteolysis activates EpCAM as a mitogenic signal transducer in vitro and in vivo. This involves shedding of its ectodomain EpEX and nuclear translocation of its intracellular domain EpICD. Cleavage of EpCAM is sequentially catalysed by TACE and presenilin-2. Pharmacological inhibition or genetic silencing of either protease impairs growth-promoting signalling by EpCAM, which is compensated for by EpICD. Released EpICD associates with FHL2, β-catenin and Lef-1 to form a nuclear complex that contacts DNA at Lef-1 consensus sites, induces gene transcription and is oncogenic in immunodeficient mice. In patients, EpICD was found in nuclei of colon carcinoma but not of normal tissue. Nuclear signalling of EpCAM explains how EpCAM functions in cell proliferation.

[1]  Xin Wei Wang,et al.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.

[2]  H. Schägger,et al.  Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. , 1991, Analytical biochemistry.

[3]  Raphael Kopan,et al.  Notch signaling: from the outside in. , 2000, Developmental biology.

[4]  B. de Strooper,et al.  The amyloid precursor protein (APP)‐cytoplasmic fragment generated by γ‐secretase is rapidly degraded but distributes partially in a nuclear fraction of neurones in culture , 2001, Journal of neurochemistry.

[5]  C. Dotti,et al.  Ripped out by presenilin-dependent γ-secretase , 2003 .

[6]  M Vasei,et al.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers , 2006, British Journal of Cancer.

[7]  Joseph Haydn,et al.  Theme and variations , 1956 .

[8]  D. Kang,et al.  Presenilins Mediate Phosphatidylinositol 3-Kinase/AKT and ERK Activation via Select Signaling Receptors , 2005, Journal of Biological Chemistry.

[9]  Jens Rauch,et al.  CK8 correlates with malignancy in leukoplakia and carcinomas of the head and neck. , 2006, Biochemical and biophysical research communications.

[10]  B. Jiang,et al.  Suppression of FHL2 expression induces cell differentiation and inhibits gastric and colon carcinogenesis. , 2007, Gastroenterology.

[11]  J. Atz,et al.  Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer , 2007, British Journal of Cancer.

[12]  Nancy Cheng,et al.  Human hepatic stem cells from fetal and postnatal donors , 2007 .

[13]  O. Gires,et al.  EpCAM (CD326) finding its role in cancer , 2007, British Journal of Cancer.

[14]  M. Aumailley,et al.  FHL2 interacts with both ADAM‐17 and the cytoskeleton and regulates ADAM‐17 localization and activity , 2006, Journal of cellular physiology.

[15]  H. van Goor,et al.  Expression of EpCAM is up‐regulated during regeneration of renal epithelia , 2008, The Journal of pathology.

[16]  P. Altevogt,et al.  L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers , 2005, The Journal of cell biology.

[17]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[18]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[19]  H. A. Bakker,et al.  Epithelial Cell Adhesion Molecule (Ep-CAM) Modulates Cell–Cell Interactions Mediated by Classic Cadherins , 1997, The Journal of cell biology.

[20]  C. Haass,et al.  SorLA Signaling by Regulated Intramembrane Proteolysis* , 2006, Journal of Biological Chemistry.

[21]  G. Sauter,et al.  High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer , 2004, Breast Cancer Research and Treatment.

[22]  P. Kenny.  TACE: a new target in epidermal growth factor receptor dependent tumors. , 2007, Differentiation; research in biological diversity.

[23]  Michael S. Wolfe,et al.  Presenilin: Running with Scissors in the Membrane , 2007, Cell.

[24]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Wolfe,et al.  Intramembrane Proteolysis: Theme and Variations , 2004, Science.

[26]  D. Baltimore,et al.  I kappa B: a specific inhibitor of the NF-kappa B transcription factor. , 1988, Science.

[27]  David Newnham,et al.  Outside in. , 2008, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[28]  P. Altevogt,et al.  A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. , 2006, The Biochemical journal.

[29]  Y. Taniguchi,et al.  Presenilin-dependent “γ-Secretase” Processing of Deleted in Colorectal Cancer (DCC)* , 2003, Journal of Biological Chemistry.

[30]  M. Bissell,et al.  Targeting TACE-dependent EGFR ligand shedding in breast cancer. , 2007, The Journal of clinical investigation.

[31]  H. Schaller,et al.  Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. , 2000, Journal of cell science.

[32]  O. Gires.  TACSTD1 (tumor-associated calcium signal transducer 1) , 2011 .

[33]  M. Gurney,et al.  The Notch Intracellular Domain Is Ubiquitinated and Negatively Regulated by the Mammalian Sel-10 Homolog* , 2001, The Journal of Biological Chemistry.

[34]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[35]  C. Eaves,et al.  Characterization of bipotent mammary epithelial progenitor cells in normal adult human breast tissue , 2001, Breast Cancer Research and Treatment.

[36]  E. Schmelzer,et al.  The Phenotypes of Pluripotent Human Hepatic Progenitors , 2006, Stem cells.

[37]  M. Buendia,et al.  Identification of the LIM Protein FHL2 as a Coactivator of β-Catenin* , 2003, The Journal of Biological Chemistry.

[38]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[40]  R. Haddon.  From the outside in , 1994, Nature.

[41]  C. Eaves,et al.  Epithelial Progenitors in the Normal Human Mammary Gland , 2005, Journal of Mammary Gland Biology and Neoplasia.

[42]  H. Clevers.  Wnt/beta-catenin signaling in development and disease. , 2006, Cell.

[43]  T M Jovin,et al.  Comparison of fixation protocols for adherent cultured cells applied to a GFP fusion protein of the epidermal growth factor receptor. , 1999, Cytometry.

[44]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[45]  R. Anderson,et al.  Expression of the homophilic adhesion molecule, Ep-CAM, in the mammalian germ line. , 1999, Journal of reproduction and fertility.

[46]  Raphael Kopan,et al.  A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. , 2000, Molecular cell.

[47]  Jide Wang,et al.  The four‐and‐a‐half‐LIM protein 2 (FHL2) is overexpressed in gliomas and associated with oncogenic activities , 2008, Glia.

[48]  Y. Taniguchi,et al.  Presenilin-dependent "gamma-secretase" processing of deleted in colorectal cancer (DCC). , 2003, The Journal of biological chemistry.

[49]  C. Dotti,et al.  RIPped out by presenilin-dependent gamma-secretase. , 2003, Cellular signalling.

[50]  M. Buendia,et al.  Identification of the LIM protein FHL2 as a coactivator of beta-catenin. , 2003, The Journal of biological chemistry.

[51]  U. Moens,et al.  The multifunctional roles of the four-and-a-half-LIM only protein FHL2 , 2006, Cellular and Molecular Life Sciences CMLS.

[52]  B. LaFleur,et al.  TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer , 2008, Clinical Cancer Research.

[53]  A. Ben-Ze'ev,et al.  The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. , 2005, Cancer research.

[54]  Markus Münz,et al.  The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation , 2004, Oncogene.

[55]  W. Birchmeier.  Cell adhesion and signal transduction in cancer , 2005, EMBO reports.

[56]  S. Hubbard.  Theme and variations: juxtamembrane regulation of receptor protein kinases. , 2001, Molecular cell.